Choate Investment Advisors Sells 122 Shares of Zimmer Biomet Holdings, Inc. (ZBH)

Choate Investment Advisors cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,007 shares of the medical equipment provider’s stock after selling 122 shares during the period. Choate Investment Advisors’ holdings in Zimmer Biomet Holdings were worth $1,285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% during the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 22 shares during the period. Parallel Advisors LLC raised its position in Zimmer Biomet Holdings by 20.8% during the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 199 shares during the period. IHT Wealth Management LLC raised its position in Zimmer Biomet Holdings by 28.4% during the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 256 shares during the period. Finally, Sandy Spring Bank raised its position in Zimmer Biomet Holdings by 1.7% during the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 85.48% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down 0.45% during mid-day trading on Friday, reaching $115.47. The company’s stock had a trading volume of 1,626,722 shares. The stock has a 50 day moving average of $114.88 and a 200-day moving average of $120.74. The stock has a market cap of $23.35 billion, a P/E ratio of 32.89 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by ($0.02). The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.83%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.

COPYRIGHT VIOLATION NOTICE: This story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/16/choate-investment-advisors-sells-122-shares-of-zimmer-biomet-holdings-inc-zbh.html.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.07% of the company’s stock.

A number of research firms have recently commented on ZBH. Stifel Nicolaus reaffirmed a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Gabelli began coverage on Zimmer Biomet Holdings in a research note on Thursday, August 24th. They set a “buy” rating and a $142.00 target price on the stock. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. BMO Capital Markets reaffirmed a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Finally, Wells Fargo & Company reaffirmed a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $136.75.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply